Use of SGLT2 inhibitors during Ramadan: An expert panel statement

Diabetes Res Clin Pract. 2020 Nov:169:108465. doi: 10.1016/j.diabres.2020.108465. Epub 2020 Sep 22.

Abstract

Fasting from dawn to sunset, during the holy month of Ramadan, constitutes one of the five main pillars in Islam and is observed by the majority of Muslims. Owing to important physiological changes, Ramadan fasting holds a crucial place in the context of diabetes management. Approximately one-fifth of the world's Muslim population resides in the Middle East and Africa (MEA) region. To discuss the challenges and management of diabetes during Ramadan fasting in the MEA region, a panel of 12 experts in the field of diabetes from across the MEA region attended two expert committee meetings held in Dubai. The key point of discussion was the safety and efficacy of the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) during Ramadan, based on outcomes of the recent clinical trials with SGLT2i. This is the first consensus recommendation on the management of diabetes with SGLT2i across the MEA region during Ramadan. The document summarizes expert views and opinions on the current management of diabetes with SGLT2i during Ramadan and aims to enhance the current knowledge and understanding on the issue of diabetes management during Ramadan. This will aid the physicians of the MEA region with appropriate decision-making for their patients during Ramadan.

Keywords: Diabetes; Fasting; Guidelines; MEA; Ramadan; SGLT2i.

Publication types

  • Review

MeSH terms

  • Africa
  • Consensus
  • Dehydration / epidemiology
  • Diabetes Mellitus / drug therapy*
  • Diabetic Ketoacidosis / epidemiology
  • Fasting*
  • Female
  • Humans
  • Hyperglycemia / epidemiology
  • Hypoglycemia / epidemiology
  • Islam*
  • Male
  • Middle East
  • Practice Guidelines as Topic*
  • Risk Factors
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
  • Urinary Tract Infections / epidemiology

Substances

  • Sodium-Glucose Transporter 2 Inhibitors